Biodexa Pharmaceuticals (BDRX) Research & Development (2013 - 2025)

Biodexa Pharmaceuticals (BDRX) has 12 years of Research & Development data on file, last reported at -$2.2 million in Q2 2025.

• For the quarter ending Q2 2025, Research & Development changed N/A year-over-year to -$2.2 million; the trailing twelve-month figure through Jun 2025 stood at -$10.7 million (changed N/A YoY), and the FY2025 full-year result was -$5.2 million, up 25.16% from the prior year.
• Research & Development climbed to -$2.2 million in Q2 2025, from -$2.8 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of -$2.2 million in Q2 2025 to a low of -$3.0 million in Q3 2022.
• A 5-year average of -$2.7 million and a median of -$2.8 million in 2024 frame the typical range for Research & Development.
• Across the five-year window, Research & Development surged 66.18% in 2021 and dropped 6.85% in 2022, its largest moves.
• Tracing BDRX's Research & Development over 5 years: stood at -$2.7 million in 2021, then declined by 4.46% to -$2.8 million in 2022, then grew by 0.48% to -$2.8 million in 2023, then advanced by 0.26% to -$2.8 million in 2024, then rose by 20.94% to -$2.2 million in 2025.
• Business Quant data shows BDRX's Research & Development at -$2.2 million in Q2 2025, -$2.8 million in Q4 2024, and -$2.8 million in Q2 2023.